Jinjun Shi is an Assistant Professor at Harvard Medical School, and directs the laboratory for Nanoengineering and Drug Delivery at Brigham and Women’s Hospital, Boston. He has published more than 25 papers and is an inventor of over 15 issued/pending patents. Some of his nanomedicine research work has formed the foundation for the launch of two biotechnology companies–Selecta Biosciences and Koan Therapeutics; and resulted in the clinical trial of a first-in-class synthetic nanoparticle vaccine for smoking cessation. He has also received many awards, including the K99/R00 Award from National Cancer Institute and Young Investigator Award from Prostate Cancer Foundation. Jinjun Shi is an Assistant Professor at Harvard Medical School, and directs the laboratory for Nanoengineering and Drug Delivery at Brigham and Women’s Hospital, Boston. He has published more than 25 papers and is an inventor of over 15 issued/pending patents. Some of his nanomedicine research work has formed the foundation for the launch of two biotechnology companies–Selecta Biosciences and Koan Therapeutics; and resulted in the clinical trial of a first-in-class synthetic nanoparticle vaccine for smoking cessation. He has also received many awards, including the K99/R00 Award from National Cancer Institute and Young Investigator Award from Prostate Cancer Foundation.

Surgery and Medicine